Sage Journals: Discover world-class research

Abstract

The presence of mutations associated with integrase inhibitor (INI) resistance among INI-naive patients may play an important clinical role in the use of those drugs Samples from 76 HIV-1-infected subjects naive to INIs were submitted to direct sequencing. No differences were found between naive (25%) subjects and subjects on HAART (75%). No primary mutation associated with raltegravir or elvitegravir resistance was found. However, 78% of sequences showed at least one accessory mutation associated with resistance. The analysis of the 76 IN sequences showed a high polymorphic level on this region among Brazilian HIV-1-infected subjects, including a high prevalence of aa substitutions related to INI resistance. The impact of these findings remains unclear and further studies are necessary to address these questions.

Get full access to this article

View all access options for this article.

References

Malet

, Soulie

, Tchertanov

et al. Structural effects of amino acid variations between B and CRF02-AG HIV-1 integrases. J Med Virol, 2008; 80:754–761.

Ceccherini-Silberstein

, Malet

, D'Arrigo

, Antinori

, Marcelin

, Perno

. Characterization and structural analysis of HIV-1 integrase conservation. AIDS Rev, 2009; 11:17–29.

Van Laethem

, Schrooten

, Covens

et al. A genotypic assay for the amplification and sequencing of integrase from diverse HIV-1 group M subtypes. J Virol Methods, 2008; 153:176–181.

Katlama

, Murphy

. Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection. Ther Clin Risk Manag, 2009; 5:331–340.

Loizidou

, Kousiappa

, Zeinalipour-Yazdi

, Van de Vijver

, Kostrikis

. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: Genetic and structural in silico analyses. Biochemistry, 2009; 48:4–6.

Herring

, Cunningham

, Dwyer

. Potential drug resistance polymorphisms in the integrase gene of HIV type 1 subtype A. AIDS Res Hum Retroviruses, 2004; 20:1010–1014.

Fikkert

, Van Maele

, Vercammen

et al. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol, 2003; 77:11459–11470.

de Oliveira

, Deforche

, Cassol

et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics, 2005; 21:3797–3800.

Rhee

, Gonzales

, Kantor

, Betts

, Ravela

, Shafer

. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res, 2003; 31:298–303.

10.

Rhee

, Liu

, Kiuchi

et al. Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors. Retrovirology, 2008; 5:74.

11.

Passaes

, Guimaraes

, Fernandez

et al. Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. J Acquir Immune Defic Syndr, 2009; 51:7–12.

12.

Myers

, Pillay

. Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol, 2008; 82:9228–9235.

13.

Eshleman

, Hudelson

, Smith

et al. Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS Res Hum Retroviruses, 2009; 25:343–345.

14.

Charpentier

, Karmochkine

, Laureillard

et al. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med, 2008; 9:765–770.

15.

Konsavage

Jr , Sudol

, Katzman

. Effects of varying the spacing within the D,D-35-E motif in the catalytic region of retroviral integrase. Virology, 2008; 379:223–233.

Genetic Diversity on the Integrase Region of the pol Gene among HIV Type 1-Infected Patients Naive for Integrase Inhibitors in São Paulo City,Brazil

Abstract

Get full access to this article

References